查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2143344

纖維母細胞生長因子（FGF）市場：依產品、產品形式、應用、最終用戶、使用方法、國家及地區分類－全球產業分析、市場規模、市場佔有率及2026年至2033年預測

Fibroblast Growth Factors Market, By Product, By Product Form, By Application, By End User, By Usage, By Country, and By Region -Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
出版日期: | 出版商: AnalystView Market Insights | 英文 295 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2025 年，纖維母細胞生長因子 (FGF) 市場價值將達到 3.106 億美元，從 2026 年到 2033 年將以 6.2% 的複合年成長率成長。

纖維母細胞生長因子 (FGF) 是一類分泌蛋白，它們透過高度依賴細胞環境的方式來活化細胞表面的蛋白酪氨酸激酶受體，從而發揮多種生物學功能，包括血管生成、創傷治療和器官發生。 FGF 分子具有典型的結構，其三葉草狀球狀結構域負責分子自身、受體和硫酸乙醯肝素輔因子之間的相互作用。球狀結構域之後的異構體特異性結構域決定了 FGF 對受體訊號傳導的影響及其作用方式（自分泌、旁分泌或內分泌訊號傳導）。由於其獨特的結構和潛在的轉譯後修飾，這些蛋白質具有獨特的性質，對幾乎所有細胞類型（包括癌組織細胞）都表現出多方面的影響。因此，FGF 被認為是治療疾病（致癌基因）、促進再生（細胞增殖和分化）以及代謝紊亂的潛在候選藥物。

纖維母細胞生長因子市場－市場動態

重組蛋白工程技術的進步正在推動市場需求。

重組蛋白工程技術的進步預計將推動纖維母細胞生長因子（FGF）市場的發展。重組蛋白工程在纖維母細胞生長因子生產中的應用將有助於高效擴大纖維母細胞的生產規模。這項技術將促進細胞和組織的生長，以及後續的治療和修復，並有助於提高用於研發和治療的纖維母細胞產品的品質。例如，根據2026年5月發布的《重組蛋白療法：2025年最新進展》報告，合成生物學、宿主細胞工程和生物製程最佳化的快速發展正在推動重組蛋白療法領域的進步。研究重點正轉向雙特異性抗體、奈米抗體、融合蛋白和自組裝生物材料。該報告還包括截至2025年美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）對生物製藥的累積和年度批准數量。這些進展可望提高FGF產品的品質、穩定性、療效和治療應用。

纖維母細胞生長因子（FGF）市場－市場區隔分析：

全球纖維母細胞生長因子 (FGF) 市場按產品、劑型、應用、最終用戶、使用方法和地區進行細分。

在應用方面，創傷治療發揮著至關重要的作用。這是因為纖維母細胞生長因子 (FGF) 能夠促進細胞增殖、細胞遷移、管狀結構形成、血管生成和組織再生，從而幫助傷口早期癒合以及皮膚和組織的修復。 2025 年 4 月，賽默飛世爾科技推出了一系列基於其 FGF-1、FGF-2、FGF-7 和 FGF-10 的重組成纖維母細胞生長因子和生長激素產品，專門用於此應用。這些因子已被證實對傷口和組織癒合至關重要。關於重組 FGF-10 蛋白，賽默飛世爾科技也強調了其在傷口創傷治療（即傷口和組織修復）中的作用。此產品系列進一步鞏固了賽默飛世爾科技在推動創傷治療和組織修復研究及應用的地位。

纖維母細胞生長因子市場—區域分析

北美憑藉其先進的醫療保健體系、發達的生物技術產業以及在研發領域的巨額投入，在成纖維母細胞生長因子（FGF）市場佔據著舉足輕重的地位。例如，根據聯合國教科文組織統計研究所的數據，預計到2026年3月，全球研發投入佔全球GDP的比例將從1.71%成長至1.92%。同時，歐洲和北美-歐洲地區的研發支出將達到GDP的2.55%，位居各地區之首。然而，仍有73%的國家研發支出佔GDP的比例不足1%。研發的重要性和價值日益凸顯，有助於北美在FGF的研究和創新領域保持領先地位。

印度纖維母細胞生長因子市場—國家概況

印度擁有龐大的老齡人口，且文明病日益增多，因此在該領域具有巨大的成長潛力。傷口管理、再生醫學和腫瘤治療等領域對先進治療技術的需求推動了這一領域的發展。根據美國國立衛生研究院（NIH）2025年1月發布的報告，印度都市區的糖尿病盛行率為11%至20%，農村地區為3%至10%。印度約有7700萬成年人患有糖尿病。心臟病約佔印度死亡人數的25%，18歲以上人口中約有25%患有高血壓。印度約有5%的人口肥胖，兒童肥胖率高達14.4%。此外，印度約有1.973億人患有精神疾病。這些國家健康趨勢無疑將增加對再生醫學和先進創傷治療治療的需求。

目錄

第1章：纖維母細胞生長因子（FGF）市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章：纖維母細胞）的主要市場趨勢

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 未來市場趨勢

第4章：纖維母細胞生長因子（FGF）的產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長前景展望圖
  • 管理體制分析

第5章：纖維母細胞生長因子（FGF）市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：纖維母細胞生長因子（FGF）市場現狀

  • 纖維母細胞生長因子（FGF）市佔率分析，2025年
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章纖維母細胞生長因子（FGF）市場：依產品分類

  • 概述
    • 基於細分市場的市佔率分析：按產品
    • FGF21
    • FGF7
    • FGF23
    • FGF1
    • FGF10
    • FGF2
    • FGF19
    • 其他

第8章纖維母細胞生長因子（FGF）市場：依產品形式分類

  • 概述
    • 基於細分市場的市場佔有率分析：按產品類型
    • 成品
    • 研究級
    • 試劑盒與診斷試劑
    • GMP級

第9章纖維母細胞生長因子（FGF）市場：依應用領域分類

  • 概述
    • 基於細分市場的市場佔有率分析：按應用領域
    • 細胞療法
    • 皮膚科
    • 腫瘤學
    • 心血管疾病與糖尿病
    • 創傷治療
    • 血液學
    • 其他

第10章纖維母細胞生長因子（FGF）市場：依最終用戶分類

  • 概述
    • 基於細分市場的市場佔有率分析：按最終用戶分類
    • 合約研究組織/合約生產組織（CRO/CMO）
    • 製藥和生物技術公司
    • 研究機構和學術機構
    • 其他

第11章纖維母細胞生長因子（FGF）市場：依用途分類

  • 概述
    • 基於細分市場的市場佔有率分析：按用途分類。
    • 局部 FGF
    • 臨床階段的應用
    • 將FGF摻入植入/支架中
    • 體內臨床前應用
    • 注射用FGF
    • 體外應用

第12章纖維母細胞生長因子（FGF）市場：依地區分類

  • 介紹
  • 北美洲
    • 概述
    • 主要製造商：北美
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 主要製造商：歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 丹麥
    • 其他歐洲國家
  • 亞太地區
    • 概述
    • 主要製造商：亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 台灣
    • 越南
    • 其他亞太國家
  • 拉丁美洲
    • 概述
    • 主要製造商：拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他拉丁美洲國家
  • 中東和非洲
    • 概述
    • 主要生產商：中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 伊朗
    • 卡達
    • 其他中東和非洲國家

第13章 主要供應商分析：纖維母細胞生長因子（FGF）產業

  • 競爭基準
    • 競爭對手儀錶板
    • 競爭定位
  • 公司簡介
    • Thermo Fisher Scientific
    • R&D Systems（Bio-Techne）
    • Merck KGaA（Sigma-Aldrich）
    • Abcam
    • Cell Signaling End User
    • GenScript Biotech
    • Lonza Group
    • Miltenyi Biotec
    • FUJIFILM Wako Pure Chemical
    • MedChemExpress
    • Proteintech Group
    • Elabscience Biotech
    • ACROBiosystems
    • STEMCELL Technologies
    • Sino Biological
    • Creative BioMart
    • BioLegend
    • Others

第14章：AnalystView 的全景視圖

簡介目錄
Product Code: ANV7588

Fibroblast Growth Factors Market size was valued at US$ 310.6 Million in 2025, expanding at a CAGR of 6.2% from 2026 to 2033.

The Fibroblast Growth Factors (FGFs) refer to the set of secreted proteins which perform a number of biological roles, such as angiogenesis, wound healing and organogenesis, through the activation of cell-surface tyrosine kinase receptors in a manner that is highly context-dependent. The FGF molecules have a typical structure where the trefoil globular domain is responsible for the interaction between the molecule itself and the receptor as well as the heparan sulphate cofactor. The globular domain is followed by the isoform-specific domains whose structure determines the way FGFs affect the receptor signalling and the mode of FGFs' action (autocrine, paracrine or endocrine signalling). The structure of the FGFs as well as the possible post-translational modifications provides these proteins with a unique property to exert a pleiotropic effect on almost all cell types, including those in cancerous tissue. Hence qualifying them as a candidate for treatment of the disease (oncogenes), regeneration (cell proliferation and differentiation) and metabolic disorders.

Fibroblast Growth Factors Market- Market Dynamics

Advancements In Recombinant Protein Engineering To Boost Market Demand

Advancements in recombinant protein engineering are expected to drive the Fibroblast Growth Factors market forward. The development of recombinant protein engineering in the production of fibroblast growth factors will help increase the production of effective and efficient fibroblasts. This type of technology helps to improve the growth of the cells and tissue, as well as their further treatment and healing, and to improve the quality of the fibroblast products for research and therapeutic purposes. For instance, in May 2026, according to the Recombinant Protein Drugs: A 2025 Update report, there has been progress in recombinant protein therapeutics because of the rapid development in synthetic biology, host cell engineering, and bioprocess optimization; the focus has shifted to bispecific antibodies, nanobodies, fusion proteins, and self-assembling biomaterials and also contains cumulative and yearly biologics approvals by both the U.S. FDA and the European Medicines Agency (EMA), which are based on data until 2025. These advancements are expected to enhance FGF product quality, stability, efficacy, and therapeutic applications.

Fibroblast Growth Factors Market- Segmentation Analysis:

The Global Fibroblast Growth Factors Market is segmented on the basis of Product, Product Form, Application, End User, Usage, and Region.

Under application, wound healing plays a key role because fibroblast growth factors (FGFs) support cell proliferation, cell migration, tube formation, angiogenesis, and tissue regeneration that assist in the quicker healing of a wound and repair of skin and tissues. In April 2025, Thermo Fisher Scientific brought out its range of recombinant fibroblast growth factors and growth hormone based on its FGF-1, FGF-2, FGF-7, and FGF-10 specifically for this use, and it has proved to be extremely important for wound and tissue healing. In the case of the FGF-10 recombinant protein, Thermo Fisher Scientific also mentions its role in wound healing, which is basically wound and tissue repair. This portfolio reinforces Thermo Fisher Scientific's role in advancing wound healing and tissue repair research applications.

Fibroblast Growth Factors Market- Geographical Insights

North America holds a notable place in the Fibroblast Growth Factors market due to its advanced healthcare sector, developed biotechnology industry, and substantial spending on research and development. For instance, in March 2026, according to the UNESCO (Org.) Institute for Statistics, the global investment in research and development grew from 1.71% to 1.92% of global GDP, while the R&D expenditure percentage of GDP value in Europe and Northern America & Europe reached 2.55%, which is the highest among all the regions. 73% of countries are still spending less than 1% of their GDP on R&D. The importance and value of R&D have grown further, which helps North America in maintaining its position in FGF research and innovation.

India Fibroblast Growth Factors Market - Country Insights

India offers huge potential for growth in this regard due to its large senior citizen population, along with an increase in lifestyle diseases. The demands are driven by the requirement of advanced treatment techniques to manage wounds, regenerative medicine & oncology. In January 2025, according to the NIH Gov report, the prevalence rate of diabetes cases in the country is between 11% and 20% in urban areas and 3% to 10% in rural areas. Some 77 million adults in India have the disease. Nearly 25% of deaths in India are caused by heart disease, and 25% of people over 18 years old suffer from hypertension. About 5% of the Indian population is obese, while 14.4% of all Indian children suffer from the disease. Around 197.3 million of the Indian population suffers from mental disorders. Such health trends among the population are bound to raise the demand for regenerative and advanced wound healing treatments.

Fibroblast Growth Factors Market- Competitive Landscape:

The Fibroblast Growth Factors market is being affected by several companies that are working towards creating further advancements in the area of protein engineering as well as in other biotechnological efforts. Some of the companies which are working towards making such advancements are Lonza Group, FUJIFILM Wako Pure Chemical, Miltenyi Biotec, Akero Therapeutics, and 89Bio Inc. These companies are trying to make advancements in the area of regenerative medicine, manufacturing methods, and treatment therapies in the areas of oncology, wound healing, and cell therapy. In September 2025, Miltenyi Biotec collaborated with Verismo Therapeutics in order to develop STAR-101 through the supply of clinical-grade lentiviral vectors. These strategic advancements are accelerating innovation and expanding therapeutic applications across the FGF market.

Recent Developments:

In January 2026, FUJIFILM Wako Pure Chemical initiated the manufacture of its GMP CHIR99021 GSK-3B inhibitor on a commercial scale for use in cell culture processes, adding to its range of reagents that facilitate the research and production of cell therapies.

In September 2025, 89bio signed a merger agreement for acquisition by Roche, integrating Roche's development, manufacturing, and marketing capabilities with 89bio's pegozafermin, an FGF21 analogue under development for MASH.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL FIBROBLAST GROWTH FACTORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Thermo Fisher Scientific
  • R&D Systems (Bio-Techne)
  • Merck KGaA (Sigma-Aldrich)
  • Abcam
  • Cell Signaling End User
  • GenScript Biotech
  • Lonza Group
  • Miltenyi Biotec
  • FUJIFILM Wako Pure Chemical
  • MedChemExpress
  • Proteintech Group
  • Elabscience Biotech
  • ACROBiosystems
  • STEMCELL Technologies
  • Sino Biological
  • Creative BioMart
  • BioLegend
  • Others

GLOBAL FIBROBLAST GR MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033

  • FGF21
  • FGF7
  • FGF23
  • FGF1
  • FGF10
  • FGF2
  • FGF19
  • Others

GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY PRODUCT FORM- MARKET ANALYSIS, 2020 - 2033

  • Finished Formulations
  • Research Grade
  • Kits & Diagnostic Reagents
  • GMP Grade

GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY APPLICATION- MARKET ANALYSIS, 2020 - 2033

  • Cell Therapy
  • Dermatology
  • Oncology
  • Cardiovascular Disease & Diabetes
  • Wound Healing
  • Hematology
  • Others

GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

  • Contract Research & Manufacturing Organizations
  • Pharmaceutical & Biotechnology Companies
  • Research Centers & Academic Institutes
  • Others

GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY USAGE- MARKET ANALYSIS, 2020 - 2033

  • Topical FGFs
  • Clinical-Stage Use
  • Implant/Scaffold-Integrated FGFs
  • In-Vivo Preclinical Use
  • Injectable FGFs
  • In-Vitro Use

GLOBAL FIBROBLAST GROWTH FACTORS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Taiwan
  • Vietnam
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Iran
  • Qatar
  • Rest of MEA

Table of Contents

1. Fibroblast Growth Factors Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Fibroblast Growth Factors Market Snippet by Product
    • 2.1.2. Fibroblast Growth Factors Market Snippet by Product Form
    • 2.1.3. Fibroblast Growth Factors Market Snippet by Application
    • 2.1.4. Fibroblast Growth Factors Market Snippet by End User
    • 2.1.5. Fibroblast Growth Factors Market Snippet by Usage
    • 2.1.6. Fibroblast Growth Factors Market Snippet by Country
    • 2.1.7. Fibroblast Growth Factors Market Snippet by Region
  • 2.2. Competitive Insights

3. Fibroblast Growth Factors Key Market Trends

  • 3.1. Fibroblast Growth Factors Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Fibroblast Growth Factors Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Fibroblast Growth Factors Market Opportunities
  • 3.4. Fibroblast Growth Factors Market Future Trends

4. Fibroblast Growth Factors Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Fibroblast Growth Factors Market : Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Fibroblast Growth Factors Market Landscape

  • 6.1. Fibroblast Growth Factors Market Share Analysis, 2025
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Fibroblast Growth Factors Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
    • 7.1.2. FGF21
    • 7.1.3. FGF7
    • 7.1.4. FGF23
    • 7.1.5. FGF1
    • 7.1.6. FGF10
    • 7.1.7. FGF2
    • 7.1.8. FGF19
    • 7.1.9. Others

8. Fibroblast Growth Factors Market - By Product Form

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Product Form, 2025 & 2033 (%)
    • 8.1.2. Finished Formulations
    • 8.1.3. Research Grade
    • 8.1.4. Kits & Diagnostic Reagents
    • 8.1.5. GMP Grade

9. Fibroblast Growth Factors Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Application, 2025 & 2033 (%)
    • 9.1.2. Cell Therapy
    • 9.1.3. Dermatology
    • 9.1.4. Oncology
    • 9.1.5. Cardiovascular Disease & Diabetes
    • 9.1.6. Wound Healing
    • 9.1.7. Hematology
    • 9.1.8. Others

10. Fibroblast Growth Factors Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
    • 10.1.2. Contract Research & Manufacturing Organizations
    • 10.1.3. Pharmaceutical & Biotechnology Companies
    • 10.1.4. Research Centers & Academic Institutes
    • 10.1.5. Others

11. Fibroblast Growth Factors Market - By Usage

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Usage, 2025 & 2033 (%)
    • 11.1.2. Topical FGFs
    • 11.1.3. Clinical-Stage Use
    • 11.1.4. Implant/Scaffold-Integrated FGFs
    • 11.1.5. In-Vivo Preclinical Use
    • 11.1.6. Injectable FGFs
    • 11.1.7. In-Vitro Use

12. Fibroblast Growth Factors Market - By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Fibroblast Growth Factors Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
    • 12.2.9. U.S.
    • 12.2.10. Canada
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Fibroblast Growth Factors Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
    • 12.3.9. Germany
    • 12.3.10. UK
    • 12.3.11. France
    • 12.3.12. Italy
    • 12.3.13. Spain
    • 12.3.14. The Netherlands
    • 12.3.15. Sweden
    • 12.3.16. Russia
    • 12.3.17. Poland
    • 12.3.18. Denmark
    • 12.3.19. Rest of Europe
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Fibroblast Growth Factors Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
    • 12.4.9. China
    • 12.4.10. India
    • 12.4.11. Japan
    • 12.4.12. South Korea
    • 12.4.13. Australia
    • 12.4.14. Indonesia
    • 12.4.15. Thailand
    • 12.4.16. Philippines
    • 12.4.17. Taiwan
    • 12.4.18. Vietnam
    • 12.4.19. Rest of APAC
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Fibroblast Growth Factors Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
    • 12.5.9. Brazil
    • 12.5.10. Mexico
    • 12.5.11. Argentina
    • 12.5.12. Colombia
    • 12.5.13. Rest of LATAM
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Fibroblast Growth Factors Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Product Form, 2020 - 2033 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Application, 2020 - 2033 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Usage, 2020 - 2033 (US$ Million)
    • 12.6.9. Saudi Arabia
    • 12.6.10. UAE
    • 12.6.11. Israel
    • 12.6.12. Turkey
    • 12.6.13. Algeria
    • 12.6.14. Egypt
    • 12.6.15. Iran
    • 12.6.16. Qatar
    • 12.6.17. Rest of MEA

13. Key Vendor Analysis- Fibroblast Growth Factors Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Thermo Fisher Scientific
    • 13.2.2. R&D Systems (Bio-Techne)
    • 13.2.3. Merck KGaA (Sigma-Aldrich)
    • 13.2.4. Abcam
    • 13.2.5. Cell Signaling End User
    • 13.2.6. GenScript Biotech
    • 13.2.7. Lonza Group
    • 13.2.8. Miltenyi Biotec
    • 13.2.9. FUJIFILM Wako Pure Chemical
    • 13.2.10. MedChemExpress
    • 13.2.11. Proteintech Group
    • 13.2.12. Elabscience Biotech
    • 13.2.13. ACROBiosystems
    • 13.2.14. STEMCELL Technologies
    • 13.2.15. Sino Biological
    • 13.2.16. Creative BioMart
    • 13.2.17. BioLegend
    • 13.2.18. Others

14. 360 Degree AnalystView

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us